Michelle C. Fox, MD

Merck & Co., Inc.
Rahway, New Jersey, United States

Disclosure information not submitted.

Presentation(s):

• 126 - Modeling Confirms Islatravir 0.25 mg Administered Daily Has No Adverse Effect on Total Lymphocyte or CD4+ T-cell Counts in People Living with HIV

  Monday, October 20, 2025
  12:15 PM - 12:20 PM US ET